ERBB2 and breast carcinoma: Unresectable or metastatic HER2-low (IHC 1+ or IHC 2 + /ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy